Sage Therapeutics Analyst Ratings
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $18
Sage Therapeutics Analyst Ratings
RBC Cuts Price Target on Sage Therapeutics to $12 From $15, Keeps Sector Perform Rating
Sage Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
SAGE Therapeutics: A Balanced Hold Rating Amidst Promising Zurzuvae Launch and Clinical Pipeline Prospects
Sage Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $23
Sage Therapeutics Analyst Ratings
Sage Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
Sage Therapeutics Analyst Ratings
Baird Maintains Neutral on Sage Therapeutics, Maintains $15 Price Target
Sell Rating on SAGE Therapeutics Amid Concerns Over Zurzuvae's Market Adoption and Safety Profile
Baird Initiates Sage Therapeutics With Neutral Rating, $15 Price Target
Sage Therapeutics Analyst Ratings
Sage Therapeutics Inc: Baird Starts Insurance with Neutral Rating and $15 Target
Sell Rating on SAGE Therapeutics Amidst High Risk and Uncertain Pipeline Success